Drugs / Camsirubicin
Camsirubicin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05043649 | Sep 2021 → Oct 2023 | soft tissue sarcoma | Monopar Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00710125 | Jan 2008 → Oct 2013 | — | Gem Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02267083 | Jan → Nov 2015 | soft tissue sarcoma | Gem Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2023-11-01 | Monopar Therapeutics | Results Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting monopartx.com ↗
So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment. |
| 2023-08-08 | Monopar Therapeutics | Results Monopar Provides Encouraging Camsirubicin Clinical Data Update monopartx.com ↗
Both patients treated to date at the 650 mg/m2 dose level have experienced tumor size reductions – of 18% and 20% respectively – after the first two cycles of camsirubicin treatment. |
| 2023-06-01 | Monopar Therapeutics | Results Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update monopartx.com ↗
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). |
| 2023-02-14 | Monopar Therapeutics | Results Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin monopartx.com ↗
To date, no drug-related cardiotoxicity has been observed with camsirubicin treatment as evaluated by the industry standard left-ventricular ejection fraction (LVEF). |
| 2023-01-18 | Monopar Therapeutics | Results Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 monopartx.com ↗
We continue to see a favorable safety profile compared to doxorubicin, and the Phase 1b data to-date shows an improvement in median progression free survival from what was observed in the prior camsirubicin Phase 2 trial (265mg/m2). |
| 2022-11-16 | Monopar Therapeutics | Results Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial monopartx.com ↗
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients. |
| 2022-02-15 | Monopar Therapeutics | Results Monopar Announces Clinical and Preclinical Program Updates monopartx.com ↗
Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed |
| 2021-08-03 | Monopar Therapeutics | Regulatory Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma monopartx.com ↗ |
| 2020-02-18 | Monopar Therapeutics | Regulatory Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma monopartx.com ↗ |
All press releases naming this drug 17 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Camsirubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05043649 ↗ |
| Known as | 5-imino-13-deoxydoxorubicin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095173 ↗ |
| Known as | GPX-150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00710125 ↗ |
| Modality | Small molecule | — CHEMBL5095173 ↗ |
| Route | Intravenous | “administered IV” NCT00710125 ↗ |